dc.description.abstract | Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results: In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford-able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or lab-oratory tests. © 2022 by Turkish Society of Medical Oncology. | en_US |
dc.department-temp | Dişel, U., Clinic of Medical Oncology, Acıbadem Adana Hospital, Adana, Turkey; Köse, F., Division of Medical Oncology, Başkent University Adana Dr. Turgut Noyan Application and Research Center, Adana, Turkey; Bilici, A., Division of Medical Oncology, İstanbul Medipol University, Faculty of Medicine, İstanbul, Turkey; Özgüroğlu, M., Division of Medical Oncology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey; Sağlam, S., Division of Medical Oncology, Demiroğlu Bilim University İstanbul Florence Nightingale Hospital, İstanbul, Turkey; Şeker, M., Division of Medical Oncology, Bezmiâlem Vakıf University, Faculty of Medicine, İstanbul, Turkey; Aksoy, S., Division of Medical Oncology, Hacettepe University Institute of Cancer, Ankara, Turkey; Tek, İ., Clinic of Medical Oncology, Medicana International Ankara Hospital, Ankara, Turkey; Mandel, N.M., Clinic of Medical Oncology, American Hospital, İstanbul, Turkey; Demir, G., Clinic of Oncology, Acıbadem Maslak Hospital, İstanbul, Turkey; Arslan, Ç., Clinic of Medical Oncology, Medical Park İzmir Hospital, İzmir, Turkey; Demiray, M., Clinic of Medical Oncology, Medicana International İstanbul Hospital, İstanbul, Turkey; Öztürk, M.A., Clinic of Oncology, VM Medical Park Pendik Hospital, İstanbul, Turkey; Salepçi, T., Clinic of Medical Oncology, İstanbul Onco | en_US |